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Abstract 27 
Background: Screening for colorectal cancer (CRC) is associated with reduced CRC mortality, 28 
but low screening rates have been reported in several settings.  29 
Objective: To assess predictors of low CRC screening in Switzerland.  30 
Design & Participants: Retrospective cohort of a random sample of 940 patients aged 50–80 31 
years followed for 2 years from 4 Swiss University primary care settings. Patients with illegal 32 
residency status and history of CRC or colorectal polyps were excluded. 33 
Main measures: We abstracted socio-demographic data of patients and physicians, patient 34 
health status and indicators derived from RAND’s Quality Assessment Tools from medical 35 
charts. We defined CRC screening as colonoscopy in last 10 years, flexible sigmoidoscopy in last 36 
5 years, or fecal occult blood testing in last 2 years. We used bivariate and multivariate logistic 37 
regression analyses.  38 
Key results: Of 940 patients (mean age 63.9 years, 42.7% women), 316 (33.6%) had CRC 39 
screening. In multivariate analysis, birthplace in a country outside of Western Europe and North 40 
America (OR 0.65, 95% CI 0.45-0.97), male gender of the physician in charge (OR 0.67, 95% CI 41 
0.50-0.91), BMI 25.0-29.9 kg/m2 (OR 0.66, CI 0.46-0.96) and ≥30.0 kg/m2 (OR 0.61, CI 0.40-42 
0.90) were associated with lower CRC screening rates. 43 
Conclusion: Obesity, overweight, birthplace outside of Western Europe and North America, and 44 
male gender of the physician in charge were associated with lower CRC screening rates in Swiss 45 
University primary care settings. Physician perception of obesity and its impact on their 46 
recommendation for CRC screening might be a target for further research.  47 
Keywords: Colorectal Cancer; Cancer Screening; Obesity48 
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Background 49 
According to the World Health Organization (WHO), colorectal cancer (CRC) is the fourth 50 
leading cause of cancer death worldwide. CRC screening using biennial fecal occult blood 51 
testing has been shown to reduce CRC related mortality by about 14% [1]. Screening 52 
colonoscopy every 10 years, flexible sigmoidoscopy every 5 years, or annual fecal occult blood 53 
testing (FOBT) have been recommended by United States (U.S.) Guidelines [2] and a European 54 
Panel [3] for patients older than 50. Several studies also support cost effectiveness of CRC 55 
screening [4,5]. However, reported screening rates stay around 55% in the U.S. [6,7] and around 56 
45% in European countries [8]. 57 
In search for a better understanding of these low rates, recent studies examined the factors 58 
associated with CRC screening. Socio-economic factors such as white ethnicity, male gender, 59 
lower age, higher education level and higher household income, and insurance coverage, were 60 
found to be associated with higher CRC screening rates in several studies in the U.S. and Canada 61 
[9–12]. Whereas presence of a chronic condition increased odds for CRC screening in one study 62 
[11], no association with the number of chronic conditions was found in another [12]. A recent 63 
review on the relationship between obesity and cancer screening found a complex pattern of 64 
positive and negative associations between CRC screening and weight status throughout the 65 
literature [13]. Several studies found that annual influenza vaccine was associated with higher 66 
CRC screening rates [9,11]. The main reasons not to perform FOBT screening were patient 67 
unawareness and physicians not recommending it [10]. 68 
Outside of Northern America, publications on correlates of CRC screening are rare. A recent 69 
Spanish study found higher education level, periodic screening for breast and cervical cancer in 70 
women, and knowledge about CRC and CRC screening to increase odds for initial participation 71 
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in a population-based screening program [14]. One study from Hong Kong found that physician 72 
factors such as experience, academic appointment and agreement with CRC screening were 73 
associated with higher screening rates [15]. However, we found no studies assessing the factors 74 
associated with CRC screening in European countries without population-based screening 75 
program, such as Switzerland. 76 
The aim of this study was to assess patient and physician factors associated with lower rate of 77 
CRC screening, in University primary care settings in Switzerland, a country without a 78 
population-based screening program.  79 
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Methods 80 
Study design and patients 81 
The study design was previously published [16]. Briefly, this retrospective cohort study aimed to 82 
assess the quality of preventive care and control of cardiovascular risk factors, and included a 83 
random sample of all patients aged 50 to 80 years old, followed up by primary care physicians 84 
(PCPs) in 4 Swiss University primary care settings in Basel, Geneva, Lausanne and Zurich 85 
during 2005 and 2006. We limited the sample to this age group in order to have a high enough 86 
prevalence of examined preventive indicators and eligibility for cancer screening. From the 87 
initial random sample of 1889 patients, we excluded patients whose medical charts could not be 88 
found (54), patients with emergency visits or nurse appointment only (125), those followed up in 89 
specialized clinics only (117) or for less than one year (591), because of a possible lack of 90 
adequate time to provide preventive care (Appendix Figure 1). For this study, we also excluded 91 
12 patients known for CRC or colorectal polyps at the beginning of the review period, as the 92 
focus was to assess cancer screening in average risk patients and not to follow up. In addition, 93 
we excluded 50 patients with irregular residency status, as insurance coverage is not guaranteed 94 
for these patients. The final sample consisted of 940 abstracted medical charts. A similar sample 95 
size was used in previous studies on quality of care based on chart abstraction [17,18]. The 96 
Institutional Review Board approved the study protocol at each site.  97 
Chart abstraction 98 
Based on previous studies on factors associated with CRC screening [9,10,15], we examined the 99 
following indicators: patient demographic characteristics, including age, gender, civil status, 100 
birthplace and occupation; characteristics of the physician in charge (defined as the physician 101 
with whom the patient had the most visits over the review period), including gender, position, 102 
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and number of visits. BMI was calculated as reported body-weight in kilograms divided by 103 
squared height in meters, or directly abstracted from the medical chart. As a surrogate to patient 104 
health status, we calculated the Charlson combined age-comorbidity index [19,20] from reported 105 
comorbid conditions and the patient’s age. As this index only captures a limited list of conditions 106 
that have a potential impact on survival, we abstracted the number of prescribed medications 107 
over the two years review period. 108 
As previously described [16], patient data were abstracted from medical charts by trained 109 
medical students using a questionnaire form similar to previous studies [17,18,21]. The 110 
questionnaire assessed the 33 selected indicators for chronic and preventive care derived from 111 
RAND’s Quality Assessment Tool System [21], as well as other covariates (demographics, co-112 
morbid conditions) based on the chart abstraction form from the Translating Research Into 113 
Action For Diabetes Study [22]. Performed CRC screening was defined as documented 114 
colonoscopy in the last 10 years, flexible sigmoidoscopy or double contrast barium enema in the 115 
last 5 years, or fecal occult blood testing in the last 2 years, based on the U.S. Preventive 116 
Services Task Force 2002 recommendation statement [23]. We considered any procedure or test 117 
regardless of their indication, as data on indications was not always available. We used the 2002 118 
recommendation statement instead of the 2008 statement [2] to measure compliance with 119 
guidelines at the time of the review period (2005–2006). Patients who refused CRC screening 120 
(n=22) were grouped with those not screened, even though screening was offered by the 121 
physician, as this information might not be systematically documented in medical charts and 122 
therefore not adequately captured by chart. To measure physician-initiated care, we repeated the 123 
analysis categorizing these patients with the performed CRC screening group in a secondary 124 
analysis. 125 
 Page 7 of 22 
As chart abstraction might underestimate quality of care by 5% to 10% compared to clinical 126 
vignettes and standardized patients [24], inter-rater reliability was assessed by repeating the chart 127 
abstraction on a random sample of patients (n=45) to detect a significant kappa value [16,25]. 128 
For CRC screening, the kappa value was 0.85. Influenza immunization indicators were validated 129 
with an external administrative register at Lausanne, as previously reported [16]. For 230 130 
patients, no BMI value could be abstracted or calculated from medical charts; we imputed these 131 
missing values by the Gaussian normal regression imputation method from known values of 132 
patient’s age, gender, weight and height. We report median, lower and upper quartile of BMI 133 
before and after imputation, and proportion of imputed BMI values for each BMI category. We 134 
categorized age of the patients in three life decades, and categorized birthplace as Switzerland or 135 
foreign country, further divided into Western European and North American countries, defined as 136 
country in the child and adult mortality stratum A according to the Annex 1 of the WHO 2003 137 
World Health Report [26], and outside of Western Europe and North America, mortality strata B 138 
– E. We dichotomized continuous variables without normal distribution, i.e. Charlson combined 139 
age-comorbidity index, the number of prescribed medications, and the number of visits to the 140 
physician in charge, according to the median, and report interquartile ranges (IQR). 141 
Statistical analyses 142 
We used descriptive statistics and bivariate analyses to characterize the sample, and performed 143 
multivariate logistical regression to analyze the predictors of adequate CRC screening. Results 144 
are reported as percentages with 95% binomial exact confidence intervals (CI). To account for 145 
clustering within each of the four University setting, we treated each site as a fixed effect. 146 
Multivariate logistic regression analysis was repeated in sensitivity analyses using measured 147 
BMI without imputation, and number of prescribed medications in addition to Charlson index. 148 
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We used Stata software (version 12.1, Stata Corp., College Station, Texas) for all statistical 149 
analyses.  150 
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Results 151 
Patient description 152 
Table 1 shows characteristics of the 940 included patients. Mean age was 63.9 years (standard 153 
deviation 8.8), and 402 patients (42.7%) were women. Median BMI was 27.9 (lower quartile: 154 
24.9, upper quartile: 31.2) before imputation and 28.2 kg/m2 (IQR 24.8 – 32.1) after imputation. 155 
Most of the care was delivered by residents (89.5% vs. 10.5% by senior residents or attending 156 
physicians) and 55.1% of patients were followed by female physicians. Annual influenza 157 
vaccination was delivered to 22.3% of patients, whereas 77.7% did not receive vaccination. 158 
Colorectal cancer screening rates 159 
Table 2 shows CRC screening rates and describes screening methods. Only 316 (33.6%) of 160 
patients eligible for CRC screening had adequate CRC screening. Refusal of CRC screening was 161 
documented in 22 patients (2.3%). Fifty six percent had a colonoscopy, 41.3% had FOBT alone 162 
or combined with endoscopy, and only 3.6% had flexible sigmoidoscopy alone. Double contrast 163 
barium enema was not used for any patient. 164 
Results of bivariate and multivariate logistical regression analyses are reported in Table 3. In 165 
bivariate analyses, being overweight (BMI 25.0 to 29.9 kg/m2) and obese (BMI ≥30.0 kg/m2) 166 
were associated with lower CRC screening rates (OR 0.64, CI 0.46 – 0.90, and OR 0.61, CI 0.43 167 
– 0.88, respectively; p for trend = 0.007). Male gender of the physician in charge (OR 0.70, CI 168 
0.53 – 0.93) was also negatively associated with CRC screening. Place of birth in a country 169 
outside of Western Europe and North America was only borderline significant (OR 0.73, 95% CI 170 
0.53 – 1.00). 171 
In multivariate logistic regression analysis, being overweight (OR 0.66, CI 0.46 – 0.96) or obese 172 
(OR 0.61, CI 0.40 – 0.90), and male gender of the physician in charge (OR 0.67, 95% CI 0.50 – 173 
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0.91; p for trend = 0.011) remained significantly associated with lower screening rates, and place 174 
of birth outside of Western Europe and North America became significant (OR 0.65, 95% CI 175 
0.45 – 0.97). 176 
The proportion of imputed BMI values was considerably higher in normal and overweight than 177 
in obese patients (23% and 34% vs. 13% respectively). A sensitivity analysis using measured 178 
BMI without imputation confirmed the association of CRC screening with obesity (OR 0.63, 179 
95% CI 0.51 – 0.99) and birthplace in a country outside of Western Europe and North America, 180 
but not with overweight and physician gender. Including the total number of medications in 181 
addition to Charlson combined age-comorbidity index did not significantly change the results. In 182 
a secondary analysis considering CRC screening proposed by the physician rather than 183 
performed screening, being overweight and obese (OR 0.65, 95% CI 0.45 – 0.93 and OR 0.62, 184 
95% CI 0.42 – 0.91), and male gender of the physician in charge (OR 0.67, 95% CI 0.50 – 0.91) 185 
were associated with CRC screening, but not with place of birth in a country outside of Western 186 
Europe and North America. 187 
188 
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Discussion 189 
We found that only about one in three patients followed up in Swiss University primary care 190 
settings were screened for CRC. This relatively low CRC screening rate is comparable to those 191 
reported in some underserved populations in the U.S. [27]. We found three characteristics to be 192 
associated with lower CRC screening rates: being overweight or obese, male gender of the 193 
physician in charge, and being born in a country outside of Western Europe and North America. 194 
None of the other measured socio-demographic factors (patient gender, occupation, civil status), 195 
nor patient health status estimated by the Charlson combined age-comorbidity index reached 196 
statistical significance. 197 
As previously hypothesized [16], the absence of a population-based CRC screening program, or 198 
the lack of systematic performance monitoring in Switzerland, might explain these low CRC 199 
screening rates. This hypothesis is also supported by findings of a Canadian study, where higher 200 
CRC screening rates were found in regions with recent implementation of a CRC screening 201 
program [11]. Also, influenza vaccination has been shown to be associated with higher CRC 202 
screening rates [9,11], but was not significant in our study, possibly due to the small sample size. 203 
The negative association between BMI and CRC screening has been reported in previous studies 204 
[28], but a recent review article by Fagan et al. showed a mixed pattern of association between 205 
weight status and CRC screening without a clear trend towards a positive or negative association 206 
throughout the literature [13]. The authors hypothesized that factors associated with CRC 207 
screening might differ according to race and gender of the studied population. Overweight 208 
persons might be less health conscious and therefore less demanding of health care. However, 209 
previous studies have shown that lack of recommendation by the physician is the most frequent 210 
reason to skip CRC screening, instead of patients not asking or refusing it [10]. Also, physicians 211 
 Page 12 of 22 
might have been less likely to recommend CRC screening to overweight and obese patients, 212 
either because they think that these patients would not want screening or because of higher 213 
priority on other medical conditions. However, in the latter case, one would expect the same to 214 
be true for patients with higher Charlson combined age-comorbidity index. This potential 215 
stigmatization of overweight and obese patients by their physicians has been documented 216 
[29,30]. 217 
Female gender of the physician in charge has been associated with higher rates of screening 218 
mammographies and cervical smears [31]. However, physician gender was not associated with 219 
CRC screening in previous studies [15]. Female physicians might be more sensitized to cancer 220 
prevention through their participation as patients in regional, population-based breast cancer 221 
screening programs in Switzerland, and well-implemented screening for cervical cancer, whereas 222 
no such program exists for cancer in men. 223 
Our finding that CRC screening is associated with birthplace outside of Western Europe and 224 
North America is consistent with previous studies that found ethnicity to be associated with CRC 225 
screening [9–12]. These studies also found other socio-demographic factors such as gender and 226 
educational level, to be predictors of CRC screening that did not reach statistical significance in 227 
our results. This might be due to the relatively small sample size. A recent review by Naylor et 228 
al. suggests that patient education and physician training in communication with patients of low 229 
health literacy are paths for improving adherence to CRC screening in ethnic minorities [32]. 230 
Our study has several limitations. A first limitation was the potential underreporting in medical 231 
charts of data such as patient refusal of screening. Process-based quality scores using abstraction 232 
of medical charts have been found to underestimate the quality of care compared to clinical 233 
vignettes and standardized patients by 5% and 10%, respectively [24]. Second, we considered 234 
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any initial sigmoidoscopy in the last 5 years or colonoscopy in the last 10 years as CRC 235 
screening, because of lack of complete data on the indication, and excluded follow-up 236 
colonoscopies for CRC or adenomatous polyps only. We therefore cannot exclude that some of 237 
these endoscopic procedures were conducted for symptomatic indications, such as rectal 238 
bleeding. Third, our results rely on imputed BMI and sensitivity analysis confirmed the 239 
association between CRC screening and obesity only, but not for overweight and physician 240 
gender. This might be due to loss of power in the statistical model (n=688) and potential 241 
underreporting of BMI in normal weight and overweight, but not for obese patients. Fourth, our 242 
sample in University primary care settings might not be representative of the general Swiss 243 
population. In fact, our sample had a high proportion of patients with migratory background 244 
(51%)  and men (57%), and a higher prevalence of obesity than in the general Swiss population 245 
(32% in our sample vs. 13% in the general Swiss population aged 55-74 years) [33]. Our model 246 
was adjusted for these characteristics. Fifth, most of the care was delivered by residents in 247 
postgraduate training. Similar to our study, a previous report on CRC screening showed no 248 
difference in screening rates between physicians with or without completed postgraduate training 249 
[15], but we did not find studies directly comparing screening rates between community-based 250 
PCPs and University-based residents within a health care system with universal coverage. Sixth, 251 
it was not possible to measure patient and physician knowledge and beliefs regarding CRC and 252 
CRC screening, as this study was based on a retrospective review of medical charts. Seventh, due 253 
to the relatively small sample size, the absence of statistical significance has to be interpreted 254 
with caution, as the study might not have enough power to detect associations in subgroups. 255 
These results may be important for clinical practice, as obesity has been suggested as a risk 256 
factor for colorectal cancer [34,35]. Physician perception of obesity and its impact on their 257 
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recommendation for CRC screening might be a target for further research. A population-based 258 
CRC screening program and a systematic performance monitoring might help improve the rate 259 
of CRC screening. 260 
261 
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Tables 
Table 1: Patient characteristics N=940 
Age (years, n, %) 
  
 
50 – 59 years 345 36.7%
 
60 – 69 years 359 38.2% 
 
70 – 80 years 236 25.1% 









divorced or separated 214 23.0% 
 
single 133 14.3% 
 
widowed 94 10.1% 
Birth place (N=930, n, %)   
 
Switzerland 453 48.7% 
 
Other country, within Western Europe and North America* 194 20.9% 
 
Other country, outside of Western Europe and North America* 283 30.4% 





retired 364 39.5% 
 
freelance, at home, or in education 112 12.2% 
 
social aid 109 11.8% 
 
unemployed 85 9.2% 
Body mass index† (n, %)   
 
<18.5 kg/m2 14 1.5% 
 
18.5 – 24.9 kg/m2 230 24.5% 
 
25.0 – 29.9 kg/m2 391 42.6% 
 
≥30.0 kg/m2 305 32.4% 
Charlson combined age-comorbidity index  
 
median, interquartile range 3 2 -  5 
Number of prescribed medications  
 
median, interquartile range 4 2 - 6 
Physician in charge‡ 
  position (N=931, n, %) resident  833 89.5%
 
 
senior resident  78 8.4% 
 
 
attending / faculty 20 2.1% 
 gender (N=939, n, %) female  517 55.1% 
 number of visits (median, interquartile range) 6 4-9 
Annual Influenza vaccination (n, %)  
 
done 210 22.3% 
 
not done  730 77.7% 
* 
 
Defined as countries in the child and adult mortality stratum A based on World Health Organization (WHO) 
mortality estimates [26]. 
† Two hundred and thirty missing values were imputed from patient age, gender, height and weight. The median 
body mass index (BMI) was 28.2 kg/m2 (interquartile range 24.8 – 32.1) before imputation and 27.9 kg/m2 
(interquartile range 24.9 – 31.3) after imputation. 
 ‡ Physician in charge is defined as the physician the patient had the most visits to. 
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Table 2: Colo-Rectal Cancer (CRC) screening N=940 
CRC screening (n, %) 
  
 
not done * 624 66.4%
 
done  316 33.6% 
Screening method (N=315, n, %)   
 
fecal occult blood test  130 41.3% 
 
colonoscopy†  173 54.9% 
 
flexible sigmoidoscopy‡ 12 3.8% 
 
double contrast barium enema  0 0% 
* Including 22 (2%) patients who had refused CRC screening. 
† In 47 patients with FOBT or sigmoidoscopy and subsequent colonoscopy, the latter was considered follow-up, 
not screening. 
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Table 3: Factors associated with colorectal cancer screening  
 Bivariate OR (95% CI) Multivariable adjusted OR§
 (95% CI) 
Age      
 
50 – 59 years 1 (ref.) 
 
 1 (ref.) 
 
 
60 – 69 years 1.45 (1.06 – 1.99)  1.29 (0.87 – 1.88) 
 
70 – 80 years 1.18 (0.82 – 1.68)  0.90 (0.55 – 1.57) 
Gender       
 
female  1 (ref.) 
 
 1 (ref.) 
 
 
male  1.04 (0.79 – 1.37)  1.01 (0.72 – 1.41) 
Civil status      
 
married  1 (ref.) 
 
 1 (ref.) 
 
 
divorced or separated  1.02 (0.73 – 1.44)  0.94 (0.66 – 1.37) 
 
widowed  1.34 (0.85 – 2.11)  1.19 (0.72 – 1.95) 
 
single  1.05 (0.70 – 1.58)  0.94 (0.60 – 1.47) 
Birth place       
 
Switzerland 1 (ref.) 
 
 1 (ref.) 
 
 
Other country, within Western Europe and 
North America* 1.02 (0.72 – 1.46) 
 
1.02 (0.70 – 1.49) 
 
Other country, outside of Western Europe 
and North America* 0.73 (0.53 – 1.00) 
 
0.65 (0.45 – 0.97) 
Occupation      
 
employed  1 (ref.) 
 
 1 (ref.) 
 
 
retired 1.28 (0.91 – 1.79)  1.32 (0.83 – 2.09) 
 
freelance, at home or in education 0.78 (0.48 – 1.28)  1.00 (0.55 – 1.81) 
 
social aid 1.10 (0.68 – 1.77)  1.10 (0.65 – 1.86) 
 
unemployed 1.11 (0.66 – 1.86)  1.13 (0.62 – 2.06) 
Body mass indexb      
 
<18.5 kg/m2 0.56 (0.17 – 1.83)  0.32 (0.09 – 1.17) 
 
18.5 – 24.9 kg/m2 1 (ref.) 
 
 1 (ref.) 
 
 
25 – 29.9 kg/m2 0.64 (0.46 – 0.90)  0.66 (0.46 – 0.96) 
 
≥30 kg/m2 0.61 (0.43 – 0.88)  0.61 (0.40 – 0.90) 
Charlson combined age-comorbidity index      
 
≤ 3 points 1 (ref.) 
 
 1 (ref.) 
 
 
> 3 points 0.85 (0.65 – 1.11)  0.80 (0.58 – 1.11) 
Physician in charge‡      
 
position resident  1 (ref.) 
 
 1 (ref.) 
 
  
senior resident 1.05 (0.65 – 1.71)  1.25 (0.74 – 2.11) 
  
attending /faculty 1.32 (0.53 – 3.28)  1.33 (0.50 – 3.57) 
 
gender female  1 (ref.) 
 
 1 (ref.) 
 
  
male 0.70 (0.53 – 0.93)  0.67 (0.50 – 0.91) 
 
≤ 6 visits during 2 years follow-up 1 (ref.)     
 
> 6 visits during 2 years follow-up 1.18 (0.90 – 1.55)  1.15 (0.86 – 1.55) 
Annual Influenza vaccination      
 
done 1 (ref.) 
 
 1 (ref.) 
 
 
not done 0.74 (0.4 – 1.01)  0.84 (0.58 – 1.20) 
* Defined as countries in the child and adult mortality stratum A based on World Health Organization (WHO) 
mortality estimates [26]. 
† Two hundred and thirty missing values were imputed from patient age, gender, height and weight. 
‡ Physician in charge is defined as the physician the patient had the most visits to. 
§ Adjusted for age, gender, civil status, occupation, birth place, BMI, Charlson combined age-comorbidity index, 
annual influenza vaccination, number of visits to the physician in charge, and function, gender and age of the 
physician in charge, using a multilevel generalized linear model and treating each site as a random effect. N=897 
due to missing values. 
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Appendix 
 
Appendix Figure 1: Flowchart from the electronic administrative data to the final sample 
